RSPO3 rearrangements in advanced colorectal cancer patients and their relationship with disease characteristics

Figure 2 Distribution of primary genetic alterations in advanced colorectal cancer by tumor location. A: Frequency of specific primary genetic alterations (driver lesions) detected by next-generation sequencing in advanced colorectal cancer patients (n = 73), categorized by the location of the primary tumor; B: Bar graph showing the percentage of cases of each of the primary genetic alterations identified in a cohort of 73 patients with advanced colorectal cancer. TP53: Tumor protein p53; BRAF: B-Raf kinase; PTPRK: Protein tyrosine phosphatase receptor type k; RSPO3: R-spondin 3; ERBB2: Erythroblastic leukemia viral oncogene homolog 2; KRAS: Kirsten rat sarcoma viral oncogene homolog; NRAS: Neuroblastoma RAS viral oncogene homolog; PIK3CA: Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha; IDH2: Isocitrate dehydrogenase 2; MAP2K1: Mitogen-activated protein kinase 1; IDH1: Isocitrate dehydrogenase 1.